TECTONIC THERAPEUTIC, INC. (TECX) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $1.68M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value (m); Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $1.68M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $1.68M |
| Deferred revenue · latest quarter (USD) | (m) | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due within 1 year (USD) | (m) | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 13.19M USD | Liabilities |
| Borrowing debt | (m) | |
| Amounts owed to suppliers | 1.68M USD | Accounts Payable, Current |
| Total deferred revenue | (m) | |
| Deferred revenue due within one year | (m) | |
| Deferred revenue due after one year | (m) | |
| Reported other obligations due within one year | (m) | |
| Reported other noncurrent obligations | (m) | Other Liabilities, Noncurrent |
| Deferred revenue included in other noncurrent obligations | (m) |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- (m)
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Operating lease obligations | $4.21M |
| Finance lease obligations | $186.00K |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $1.68M | (m) | (m) | (m) | $13.19M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $2.55M | (m) | (m) | (m) | $16.16M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $1.09M | (m) | (m) | (m) | $9.71M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $1.49M | (m) | (m) | (m) | $9.47M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $2.80M | (m) | (m) | (m) | $11.55M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $6.25M | (m) | (m) | (m) | $13.79M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $976.00K | (m) | (m) | (m) | $12.13M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $2.63M | (m) | (m) | (m) | $18.36M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $4.09M | (m) | (m) | (m) | $27.54M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $243.00K | (m) | (m) | (m) | $3.51M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $27.00K | (m) | (m) | (m) | $6.35M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $910.00K | (m) | (m) | (m) | $7.66M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $1.07M | (m) | (m) | (m) | $11.80M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $591.00K | (m) | (m) | (m) | $30.01M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $384.00K | (m) | (m) | (m) | $28.58M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $1.81M | (m) | (m) | (m) | $31.41M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $28.00K | (m) | (m) | (m) | $27.90M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $4.04M | (m) | (m) | (m) | $32.18M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $3.49M | (m) | (m) | (m) | $34.36M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $2.97M | (m) | (m) | (m) | $22.88M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $2.03M | (m) | (m) | (m) | $17.10M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $2.70M | (m) | (m) | (m) | $12.98M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $2.68M | (m) | (m) | (m) | $16.89M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $2.31M | (m) | (m) | (m) | $25.38M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $2.62M | (m) | (m) | (m) | $15.78M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $2.13M | (m) | (m) | (m) | $13.20M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $3.95M | (m) | (m) | (m) | $14.50M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $1.41M | (m) | (m) | (m) | $10.45M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $2.57M | (m) | (m) | (m) | $9.36M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $3.46M | (m) | (m) | (m) | $10.58M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $2.78M | (m) | (m) | (m) | $11.29M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $1.58M | (m) | (m) | (m) | $6.16M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $4.19M | (m) | (m) | (m) | $10.41M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $527.00K | (m) | (m) | (m) | $3.66M | (m) | (m) | (m) | $500.00K | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |